CYP19A1 and breast cancer: This multicentre, open-label trial treated advanced breast cancer patients with Irosustat (oral, 40 mg/day) combined with first-line aromatase inhibitors to assess evident clinical benefit in attempts to further ablate circulating E2 concentrations.